All Stories

  1. Why intrinsic reduced susceptibility in rare fungal pathogens should be differentiated from intrinsic resistance: an ISHAM conceptual framework and narrative review
  2. Non-Candida fungal cholecystitis - an uncommon occurrence even in the right host
  3. Cryptosporidiosis in Inborn Errors of Immunity: A Single Center Cohort and Review of the Literature
  4. Closing the gap on antifungal resistance
  5. Assessment of skin yeast colonization and its predisposing factors among neonates admitted to the neonatal intensive care unit
  6. Beyond Fumigatus : a molecular portrait of clinical Aspergillus diversity, pathogenicity, and antifungal resistance
  7. Neutralizing GM-CSF autoantibodies impair neutrophil antifungal effector function in a patient with aspergillosis
  8. Spectrum of clinically significant melanized fungi in NIH hospitalized patients and their antifungal susceptibility profiles
  9. Establishment of epidemiological cutoff values for Fonsecaea pedrosoi , the primary etiologic agent of chromoblastomycosis, and eight antifungal medications
  10. Clinical significance and antifungal susceptibility profile of 103 clinical isolates of Scedosporium species complex and Lomentospora prolificans obtained from NIH patients
  11. Characterization of COVID‐19‐Associated Candidemia Among Burn Patients
  12. Acanthamoeba Infection in a Hematopoietic Cell Transplant Recipient: Challenges in Diagnosis, Management, and Source Identification
  13. Asymptomatic colonization of stray dogs and domestic cats with Trichophyton mentagrophytes II in Northern Iran
  14. Mucor germinans, a novel dimorphic species resembling Paracoccidioides in a clinical sample: questions on ecological strategy
  15. Development and preclinical validation of 2-deoxy 2-[ 18 F]fluorocellobiose as an Aspergillus -specific PET tracer
  16. Multi‐state evaluation of Candida infections in burn patients
  17. High Prevalence of Terbinafine Resistance Among Trichophyton mentagrophytes/T. interdigitale Species Complex, a Cross-Sectional Study from 2021 to 2022 in Northern Parts of Iran
  18. Molecular Epidemiology and Antifungal Susceptibility Profile in Nakaseomyces glabrata Species Complex: A 5‐Year Countrywide Study
  19. Reply to Kidd et al., “Inconsistencies within the proposed framework for stabilizing fungal nomenclature risk further confusion”
  20. Tinea capitis due to Microsporum ferrugineum: A case of unusual laboratory finding on direct microscopic examination of infected hairs and skin lesions
  21. Multi-drug resistance Trichophyton indotineae in a stray dog
  22. 2758. Clinical Significance and Antifungal Susceptibility Profile of 103 Clinical Scedosporium Species Complex and Lomentospora prolificans Isolated from NIH Hospitalized Patients
  23. A conceptual framework for nomenclatural stability and validity of medically important fungi: a proposed global consensus guideline for fungal name changes supported by ABP, ASM, CLSI, ECMM, ESCMID-EFISG, EUCAST-AFST, FDLC, IDSA, ISHAM, MMSA, and MSGERC
  24. Central nervous system Aspergillus quadrilineatus infection in a COVID‐19 patient, a case report and literature review
  25. Successful Treatment of Paecilomyces variotii Pneumonia and Lupus Nephritis With Posaconazole-Cyclophosphamide Co-administration Without Drug Interaction–Induced Toxicity
  26. Treatment recommendations for non-HIV associated cryptococcal meningoencephalitis including management of post-infectious inflammatory response syndrome
  27. P148 Emerging and cryptic Aspergillus species isolated from hospitalized patients with underlying primary immunodeficiencies
  28. S10.5d Disseminated pulmonary infection due to Mortierella wolfii in a 6-year-old patient with X-linked CGD receiving MUD-HSCT
  29. P081 Azole-resistant Aspergillus fumigatus among NIH hospitalized patients with underlying primary immunodeficiencies
  30. Development of RFLP method for rapid differentiation of Aspergillus flavus and Aspergillus oryzae, two species with high importance in clinical and food microbiology
  31. An overview of COVID-19 related to fungal infections: what do we know after the first year of pandemic?
  32. Control of Human and Animal Aspergillosis – a Health Approach
  33. Differentiation of Aspergillus flavus from Aspergillus oryzae Targeting the cyp51A Gene
  34. In Vivo Efficacy of Olorofim against Systemic Scedosporiosis and Lomentosporiosis
  35. Genotyping and In Vitro Antifungal Susceptibility Profile of Neoscytalidium Species Isolates from Respiratory Tract
  36. Recognition of Diagnostic Gaps for Laboratory Diagnosis of Fungal Diseases: Expert Opinion from the Fungal Diagnostics Laboratories Consortium (FDLC)
  37. Cutaneous hyalohyphomycosis due to Petriella setifera following traumatic inoculation in an immunocompetent host
  38. Antifungal Susceptibility Profiles of Olorofim (Formerly F901318) and Currently Available Systemic Antifungals against Mold and Yeast Phases of Talaromyces marneffei
  39. Antifungal Drugs
  40. Recent Advances in Genome Editing Tools in Medical Mycology Research
  41. Diagnosis of allergic bronchopulmonary aspergillosis in patients with persistent allergic asthma using three different diagnostic algorithms
  42. Estimating global injuries morbidity and mortality: methods and data used in the Global Burden of Disease 2017 study
  43. Author Correction: Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017
  44. Global injury morbidity and mortality from 1990 to 2017: results from the Global Burden of Disease Study 2017
  45. Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017
  46. Multicenter Cryptococcal Antigen Screening of HIV-Infected Patients in Iran
  47. Cryptococcus and cryptococcosis in Iran during 1969–2019: A systematic review and meta-analysis
  48. Annotated Genome Sequence of Aspergillus tanneri NIH1004
  49. Quantifying risks and interventions that have affected the burden of diarrhoea among children younger than 5 years: an analysis of the Global Burden of Disease Study 2017
  50. Quantifying risks and interventions that have affected the burden of lower respiratory infections among children younger than 5 years: an analysis for the Global Burden of Disease Study 2017
  51. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium
  52. Molecular epidemiology and antifungal susceptibility profiles of clinical Cryptococcus neoformans/Cryptococcus gattii species complex
  53. Cryptococcus neoformans Recovered From Olive Trees (Olea europaea) in Turkey Reveal Allopatry With African and South American Lineages
  54. Genetic diversity and antifungal susceptibility patterns of Aspergillus nidulans complex obtained from clinical and environmental sources
  55. Mapping 123 million neonatal, infant and child deaths between 2000 and 2017
  56. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017
  57. Discrimination of Aspergillus flavus from Aspergillus oryzae by matrix‐assisted laser desorption/ionization time‐of‐flight (MALDI‐TOF) mass‐spectrometry
  58. National trends in incidence, prevalence and disability-adjusted life years of invasive aspergillosis in Iran: a systematic review and meta-analysis
  59. Cryptococcus neoformans recovered from olive trees ( Olea europaea ) in Turkey reveal allopatry with African and South American lineages
  60. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017
  61. The global burden of childhood and adolescent cancer in 2017: an analysis of the Global Burden of Disease Study 2017
  62. Identification of clinical dermatophyte isolates obtained from Iran by matrix-assisted laser desorption/ionization time-offlight mass spectrometry
  63. Department of Error
  64. Efficacy of Olorofim (F901318) against Aspergillus fumigatus , A. nidulans , and A. tanneri in Murine Models of Profound Neutropenia and Chronic Granulomatous ...
  65. Ochroconis globalis infecting Atlantic salmon ( Salmo salar ), with a review of Ochroconis species in cold‐blooded animals
  66. Antifungal Susceptibility Profile of Candida Albicans Isolated from Vulvovaginal Candidiasis in Xinjiang Province of China
  67. Fungal epidemiology in cystic fibrosis patients with a special focus on Scedosporium species complex
  68. Mortality, morbidity, and hospitalisations due to influenza lower respiratory tract infections, 2017: an analysis for the Global Burden of Disease Study 2017
  69. Aspergillosis in Humans and Animals
  70. Global, regional, and national burden of tuberculosis, 1990–2016: results from the Global Burden of Diseases, Injuries, and Risk Factors 2016 Study
  71. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017
  72. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease ...
  73. Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  74. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
  75. Measuring progress of the health-related Sustainable Development Goals for 195 countries
  76. Department of Error
  77. Burden of fungal infections in Iran
  78. MGL_3741 gene contributes to pathogenicity of Malassezia globosa in pityriasis versicolor
  79. Estimated burden of serious human fungal diseases in Turkey
  80. Emerging Aspergillus Species Almost Exclusively Associated With Primary Immunodeficiencies
  81. In-vitro antifungal susceptibility testing of lanoconazole and luliconazole against Aspergillus flavus as an important agent of invasive aspergillosis
  82. Corrigendum: Fungal infections in animals: a patchwork of different situations
  83. Genetic Diversity and Antifungal Susceptibility of Candida parapsilosis Sensu Stricto Isolated from Bloodstream Infections in Turkish Patients
  84. Genetic diversity and antifungal susceptibility of Candida albicans isolated from Iranian patients
  85. Exogenous Stimulation of Type I Interferon Protects Mice with Chronic Granulomatous Disease from Aspergillosis through Early Recruitment of Host-Protective Neutrophils into the Lung
  86. Combination of Amphotericin B and Terbinafine against Melanized Fungi Associated with Chromoblastomycosis
  87. Fungal infections in animals: a patchwork of different situations
  88. Predominance of non- fumigatus Aspergillus species among patients suspected to pulmonary aspergillosis in a tropical and subtropical region of the Middle East
  89. Overview of selected virulence attributes in Aspergillus fumigatus , Candida albicans , Cryptococcus neoformans , Trichophyton rubrum , and Exophiala dermatitidis
  90. Biofilm Formation and Resistance to Fungicides in Clinically Relevant Members of the Fungal Genus Fusarium
  91. Aspergillus fumigatus alkaline protease 1 (Alp1/ Asp f13 ) in the airways correlates with asthma severity
  92. Antifungal Use in Veterinary Practice and Emergence of Resistance
  93. Cryptococcosis: Emergence of Cryptococcus gattii in Animals and Zoonotic Potential
  94. Emerging and Epizootic Fungal Infections in Animals
  95. Defective calcineurin/NFAT signaling in myeloid cells and susceptibility to aspergillosis in post-transplant patients
  96. Absent in vitro interaction between chloroquine and antifungals against Aspergillus fumigatus
  97. Effect of involved Aspergillus species on galactomannan in bronchoalveolar lavage of patients with invasive aspergillosis
  98. Successful treatment of azole-resistant invasive aspergillosis in a bottlenose dolphin with high-dose posaconazole
  99. In Vivo Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis
  100. Genetic Diversity and In Vitro Antifungal Susceptibility of 200 Clinical and Environmental Aspergillus flavus Isolates
  101. Azole Resistance in Aspergillus fumigatus: Mechanisms, Route of Resistance Selection, and Clinical Implications
  102. In Vitro Antifungal Susceptibility Profiles of 12 Antifungal Drugs against 55 Trichophyton schoenleinii Isolates from Tinea Capitis Favosa Patients in Iran, Turkey, and China
  103. Topical and systemic antifungals in dermatology practice
  104. Systemic Antifungal Agents: Current Status and Projected Future Developments
  105. Aspergillus flavus Keratitis: Experience of a Tertiary Eye Clinic in Turkey
  106. Pharmacodynamics of Voriconazole against Wild-Type and Azole-Resistant Aspergillus flavus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis
  107. Discrimination of Aspergillosis, Mucormycosis, Fusariosis, and Scedosporiosis in Formalin-Fixed Paraffin-Embedded Tissue Specimens by Use of Multiple Real-Time Quantitative PCR Assays
  108. Virulence Attributes and Antifungal Susceptibility Profile of Opportunistic Fungi Isolated from Ophthalmic Infections
  109. Genotyping and In Vitro Antifungal Susceptibility Testing of Fusarium Isolates from Onychomycosis in India
  110. Conventional Morphology Versus PCR Sequencing, rep-PCR, and MALDI-TOF-MS for Identification of ClinicalAspergillusIsolates Collected Over a 2-Year Period in a University Hospital at Kayseri, Turkey
  111. Combination of Amphotericin B and Flucytosine against Neurotropic Species of Melanized Fungi Causing Primary Cerebral Phaeohyphomycosis
  112. A 9-Month-Old Girl from Iran with Extensive Erythematous Plaques Due to Trichophyton simii, a Zoophilic Dermatophyte
  113. Time-Kill Kinetics and In Vitro Antifungal Susceptibility of Non-fumigatus Aspergillus Species Isolated from Patients with Ocular Mycoses
  114. Infrequent Production of Xanthomegnin by Fungal Strains Recovered from Patients with Ocular Mycoses
  115. Pharmacodynamics of Ceftazidime and Avibactam in Neutropenic Mice with Thigh or Lung Infection
  116. Quantitative Analysis of Single-Nucleotide Polymorphism for Rapid Detection of TR34/L98H- and TR46/Y121F/T289A-Positive Aspergillus fumigatus Isolates Obtained from Patients in Iran from 2010 to 2014
  117. Dermatophytosis due to Microsporum incurvatum: Notification and Identification of a Neglected Pathogenic Species
  118. ATR-FTIR Spectroscopy Highlights the Problem of Distinguishing Between Exophiala dermatitidis and E. phaeomuriformis Using MALDI-TOF MS
  119. Molecular Characterization and In Vitro Antifungal Susceptibility of 316 Clinical Isolates of Dermatophytes in Iran
  120. Clinical and Laboratory Features of Six Cases of Candida and Dermatophyte Folliculitis and a Review of Published Studies
  121. Aspergillusand aspergilloses in wild and domestic animals: a global health concern with parallels to human disease
  122. Epidemiological changes in tinea capitis over the sixty years of economic growth in China
  123. International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus
  124. Emergence of fusarioses in a university hospital in Turkey during a 20-year period
  125. Neglected fungal zoonoses: hidden threats to man and animals
  126. Comparison of theIn VitroActivities of Newer Triazoles and Established Antifungal Agents against Trichophyton rubrum
  127. Plasma and Epithelial Lining Fluid Pharmacokinetics of Ceftolozane and Tazobactam Alone and in Combination in Mice
  128. Pharmacodynamics of Isavuconazole in an Aspergillus fumigatus Mouse Infection Model
  129. Pharmacokinetics and Penetration of Ceftazidime and Avibactam into Epithelial Lining Fluid in Thigh- and Lung-Infected Mice
  130. Azole Resistance in Aspergillus fumigatus: Mechanisms, Route of Resistance Selection, and Clinical Implications
  131. Candida ve Kandidoz: Epidemiyoloji, Tanı, Tedavi, Antifungal İlaç Direnci ve Konağın Genetik Yatkınlığında Güncel Durum
  132. Posaconazole Prophylaxis in Experimental Azole-Resistant Invasive Pulmonary Aspergillosis
  133. In vitro antifungal susceptibility of Trichophyton violaceum isolated from tinea capitis patients
  134. Isavuconazole, a broad-spectrum triazole for the treatment of systemic fungal diseases
  135. The role of azoles in the management of azole-resistant aspergillosis: From the bench to the bedside
  136. Black Yeasts and Their Filamentous Relatives: Principles of Pathogenesis and Host Defense
  137. Effects of Low-Level Laser Irradiation on the Pathogenicity ofCandida albicans:In Vitro and in VivoStudy
  138. Antifungal Susceptibility Patterns of Opportunistic Fungi in the Genera Verruconis and Ochroconis
  139. Intrapulmonary Posaconazole Penetration at the Infection Site in an Immunosuppressed Murine Model of Invasive Pulmonary Aspergillosis Receiving Oral Prophylactic Regimens
  140. Continuous Infusion of Amphotericin B Deoxycholate for the Treatment of Life-ThreateningCandidaInfections
  141. Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis
  142. Azole-ResistantAspergillus fumigatus, Iran
  143. Pharmacodynamics and Dose-Response Relationships of Liposomal Amphotericin B against Different Azole-Resistant Aspergillus fumigatus Isolates in a Murine Model of Disseminated Aspergillosis
  144. Phaeohyphomycoses, Emerging Opportunistic Diseases in Animals
  145. In Vitro Interaction of Voriconazole and Anidulafungin against Triazole-Resistant Aspergillus fumigatus
  146. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis
  147. Pharmacodynamics of Anidulafungin against Clinical Aspergillus fumigatus Isolates in a Nonneutropenic Murine Model of Disseminated Aspergillosis
  148. Multiple subcutaneous cysts due toExophiala spiniferain an immunocompetent patient
  149. Waterborne Exophiala species causing disease in cold-blooded animals
  150. Assessment of efficacy of antifungals in experimental models of invasive aspergillosis in an era of emerging resistance: the value of real-time quantitative PCR
  151. Exophiala sideris, a novel black yeast isolated from environments polluted with toxic alkyl benzenes and arsenic